

NOVEL APPROACH FOR CHRONIC WOUND TREATMENT BY AUTOLOGOUS TRANSPLANTATION

I read the recent pilot report on the novel approach for chronic wound treatment with great interest. Shukla and colleagues¹ concluded that “Autologous noncultured epidermal cell suspension transplantation seems to be an effective, simple and time-saving method to treat chronic non-healing wounds.”¹ Indeed, the autologous cell transplantation is a new approach for medical treatment. It is reported to be an acceptable one-step process for treatment of wounds in animal models.² However, there are some concerns on the use of this technique in humans. First, both subjective and objective assessment on the outcome should be performed to ascertain the effectiveness of this technique.³ Second, the cell concentration and dosage is an important factor of concern in this specific therapeutic approach.⁴ Third, it would be interesting to know the cost and cost-effectiveness of this new technique.

Viroj Wiwanitkit, MD
Wiwanitkit House
Bangkhuae, Bangkok
Thailand

Competing interests: None declared.

References

1. Shukla VK, Tiwary SK, Barnwal S, et al. Effect of autologous epidermal cell suspension transplantation in chronic nonhealing wounds: a pilot study. *Can J Surg* 2010;53:6-10.
2. Wood FM, Stoner ML, Fowler BV, et al. The use of a non-cultured autologous cell suspension and Integra dermal regeneration template to repair full-thickness skin wounds in a porcine model: a one-step process. *Burns* 2007;33:693-700.
3. van Geel N, Ongenaes K, Vander Haeghen Y, et al. Subjective and objective evaluation of noncultured epidermal cellular grafting for repigmenting vitiligo. *Dermatology* 2006; 213:23-9.
4. Tegta GR, Parsad D, Majumdar S, et al. Efficacy of autologous transplantation of noncultured epidermal suspension in two different dilutions in the treatment of vitiligo. *Int J Dermatol* 2006;45:106-10.

DRS. SHUKLA AND PANDEY REPLY

We thank Prof. Wiwanitkit, who has taken keen interest in our article, for his appreciation and constructive comments. He has raised some concerns on the use of this technique in humans: the assessment of the outcome, cell dosage, cost and cost-effectiveness. We have already mentioned that the study was a pilot study that demonstrated the effectiveness of the technique; however, we did not quantify the cell dosage and cost-effectiveness. To address this we are evaluating the cell count/cm² and the cost-effectiveness of the technique in phase II of the study, the results of which will be communicated on completion of the study.

Vijay K. Shukla, MS, MCh (Wales)
Department of Genral Surgery
Shyam S. Pandey, MD
Department of Dermatology and Venereology
Institute of Medical Sciences
Banaras Hindu University
Varanasi, India

Competing interests: None declared.